Traditionally, safety evaluation at the early stage of drug discovery research has been
done using
in silico
,
in vitro
, and
in
vivo
systems in this order because of limitations on the amount of compounds
available and the throughput ability of the assay systems. While these
in
vitro
assays are very effective tools for detecting particular tissue-specific
toxicity phenotypes, it is difficult to detect toxicity based on complex mechanisms
involving multiple organs and tissues. Therefore, the development of novel high throughput
in vivo
evaluation systems has been expected for a long time. The
zebrafish (
Danio rerio
) is a vertebrate with many attractive
characteristics for use in drug discovery, such as a small size, transparency, gene and
protein similarity with mammals (80% or more), and ease of genetic modification to
establish human disease models. Actually, in recent years, the zebrafish has attracted
interest as a novel experimental animal. In this article, the author summarized the
features of zebrafish that make it a suitable laboratory animal, and introduced and
discussed the applications of zebrafish to preclinical toxicity testing, including
evaluations of teratogenicity, hepatotoxicity, and nephrotoxicity based on morphological
findings, evaluation of cardiotoxicity using functional endpoints, and assessment of
seizure and drug abuse liability.